Risultati per: Studio chiarisce come l’Alzheimer si diffonde nel cervello

Does AD change the gut microbiome, or does the gut microbiome influence risk for developing AD?

Objective
Estimate the prevalence of diagnosed Alzheimer’s disease (AD) and early Alzheimer’s disease (eAD) overall and stratified by age, sex and deprivation and combinations thereof in England on 1 January 2020.

Design
Cross-sectional.

Setting
Primary care electronic health record data, the Clinical Practice Research database linked with secondary care data, Hospital Episode Statistics (HES) and patient-level deprivation data, Index of Multiple Deprivation (IMD).

Outcome measures
The prevalence per 100 000 of the population and corresponding 95% CIs for both diagnosed AD and eAD overall and stratified by covariates. Sensitivity analyses were conducted to assess the sensitivity of the population definition and look-back period.

Results
There were 448 797 patients identified in the Clinical Practice Research Datalink that satisfied the study inclusion criteria and were eligible for HES and IMD linkage. For the main analysis of AD and eAD, 379 763 patients are eligible for inclusion in the denominator. This resulted in an estimated prevalence of diagnosed AD of 378.39 (95% CI, 359.36 to 398.44) per 100 000 and eAD of 292.81 (95% CI, 276.12 to 310.52) per 100 000. Prevalence estimates across main and sensitivity analyses for the entire AD study population were found to vary widely with estimates ranging from 137.48 (95% CI, 127.05 to 148.76) to 796.55 (95% CI, 768.77 to 825.33). There was significant variation in prevalence of diagnosed eAD when assessing the sensitivity with the look-back periods, as low as 120.54 (95% CI, 110.80 to 131.14) per 100 000, and as high as 519.01 (95% CI, 496.64 to 542.37) per 100 000.

Conclusions
The study found relatively consistent patterns of prevalence across both AD and eAD populations. Generally, the prevalence of diagnosed AD increased with age and increased with deprivation for each age category. Women had a higher prevalence than men. More granular levels of stratification reduced patient numbers and increased the uncertainty of point prevalence estimates. Despite this, the study found a relationship between deprivation and prevalence of AD.

E’ l’endotelina, studi anche per calvizie e insonnia

Riduce anche pericolo di patologie e morte neonatali

This Medical News story examines the complexity of determining who to treat with lecanemab, the new Alzheimer disease drug.

Irccs Meldola coordina progetto internazionale. Fondo di 6 mln da Ue

L’illuminazione artificiale interferisce con il ritmo circadiano

This Viewpoint discusses how the design of the Centers for Medicare & Medicaid Services (CMS) registry could impact Medicare’s ability to evaluate whether monoclonal antibodies are reasonable and necessary for patients with Alzheimer disease and help physicians understand when the drug is most beneficial.

Giorlandino, ‘nuovo test. Consigliato in caso di anomalie’

This Medical News feature discusses a Quest Diagnostics blood biomarkers test that is supposed to help consumers assess their Alzheimer disease risk.

Possibile ruolo contro Alzheimer e Parkinson

Lodi, numeri di casi altissimi e in crescente aumento.

Per la campagna Non ti scordar di Te cover disegnate da pazienti

Lodi, numeri di casi altissimi e in crescente aumento.

Lodi, numeri di casi altissimi e in crescente aumento.

Dodici fattori di rischio rallentano o evitano la malattia